试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
编号:NCT04182516登记状态:提前终止企业 / 申办者:Nerviano Medical Sciences
药物 / 成分:NMS-03305293
登记的停止原因(原文):The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity
编号:NCT04199351登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:AMG 171、Placebo
登记的停止原因(原文):Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body
编号:NCT04232839登记状态:提前终止企业 / 申办者:Boehringer Ingelheim
药物 / 成分:BI 894416 Reference Formulation、BI 894416 Formulation A2、BI 894416 Formulation C2、BI 894416 Formulation D2
登记的停止原因(原文):Due to company decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
编号:NCT04240210登记状态:提前终止企业 / 申办者:Midland Research Group, Inc.
药物 / 成分:Symtuza
登记的停止原因(原文):Lack of eligible enrollees/ Halted by Primary Sponsor
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
编号:NCT04272242登记状态:提前终止企业 / 申办者:National Institute of Allergy and Infectious Diseases (NIAID)
药物 / 成分:Dolutegravir (DTG)、Isoniazid (INH)、Rifapentine (RPT)、Antiretroviral Therapy (ART)
登记的停止原因(原文):Opening of Arm 2 was dependent upon assessment of DTG pharmacokinetics (PK) data from participants in Arm 1. Arm 1 is complete and results are reported. Arm 2 was not conducted based on the Arm 1 PK assessment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants
编号:NCT04323124登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-07059013、Placebo
登记的停止原因(原文):Study was terminated as it did not demonstrate sufficient pharmacological effect. Termination was not related to safety reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
编号:NCT04356352登记状态:提前终止企业 / 申办者:Wake Forest University Health Sciences
药物 / 成分:Lidocaine、Esmolol、Placebo
登记的停止原因(原文):feasibility of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
编号:NCT04531176登记状态:提前终止企业 / 申办者:The Cleveland Clinic
药物 / 成分:Weight Management Program (WMP)、Traditional care、Phentermine / Topiramate Extended Release Oral Capsule、naltrexone/bupropion extended-release
登记的停止原因(原文):After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)
编号:NCT04609943登记状态:提前终止企业 / 申办者:Bayer
药物 / 成分:BAY1211163
登记的停止原因(原文):Company Decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
编号:NCT04659044登记状态:提前终止企业 / 申办者:Academic and Community Cancer Research United
药物 / 成分:Polatuzumab Vedotin、Rituximab、Rituximab and Hyaluronidase Human、Venetoclax
登记的停止原因(原文):Trial closed due to low accrual rate
查看官方原始记录 ↗